1. Clinical & Scientific Overview
Prednisolone (TIP-MED-000094, Reference Code [6.4]) is classified under
Thyroid, Pituitary, Adrenal & Hormonal Medicines (Ch 06) as a Intermediate-Acting Systemic Corticosteroid (Glucocorticoid Anti-Inflammatory & Immunosuppressant).
Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 06 [6.4], p. 73): Wysolone (Pfizer), Omnacortil (Macleods), Kidpred, Predmet (Note: Methylprednisolone [Medrol - Pfizer, Zempred] is 20% more potent by weight: 4 mg Methylprednisolone = 5 mg Prednisolone) — Strengths & Dosage Forms: Oral Uncoated / Dispersible Tablets: 5 mg, 10 mg, 20 mg, 30 mg, 40 mg; Oral Syrup: 5 mg/5 mL, 15 mg/5 mL; Ophthalmic Drops (Pred Forte 1%)
Oral Uncoated / Dispersible Tablets: 5 mg, 10 mg, 20 mg, 30 mg, 40 mg; Oral Syrup: 5 mg/5 mL, 15 mg/5 mL; Ophthalmic Drops (Pred Forte 1%)
3. Mechanism of Action & Pharmacodynamics
Intermediate-Acting Systemic Corticosteroid (Glucocorticoid Anti-Inflammatory & Immunosuppressant) acting on target receptor/enzyme pathways in Thyroid, Pituitary, Adrenal & Hormonal Medicines (Ch 06): clinical efficacy is mediated via Intermediate-Acting Systemic Corticosteroid (Glucocorticoid Anti-Inflammatory & Immunosuppressant) for Acute exacerbations of bronchial asthma and COPD; rheumatoid arthritis, polymyalgia rheumatica, systemic lupus erythematosus (SLE), and vasculitis; nephrotic syndrome; inflammatory bowel disease; Bell's palsy; severe allergic/autoimmune dermatoses; post-transplant immunosuppression..
4. Therapeutic Indications & Evidence-Supported Uses
- Acute exacerbations of bronchial asthma and COPD
- rheumatoid arthritis, polymyalgia rheumatica, systemic lupus erythematosus (SLE), and vasculitis
- nephrotic syndrome
- inflammatory bowel disease
- Bell's palsy
- severe allergic/autoimmune dermatoses
- post-transplant immunosuppression
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Highly indication-dependent! Acute Asthma/COPD Exacerbation: 30 mg–40 mg once daily for 5–7 days. Autoimmune/Nephrotic High-Dose: 0.5–1 mg/kg/day (40–60 mg OD) followed by gradual tapering. Rheumatoid Arthritis Low-Dose Bridge: 5 mg–7.5 mg OD. Follow physician's exact dose and taper schedule.
Administration & Meal Timing: Take WITH FOOD or MILK as a single morning dose between 07:00 and 08:00 AM (mimics physiological endogenous cortisol peak and minimises hypothalamic-pituitary-adrenal [HPA] axis suppression and nocturnal insomnia). | Single Morning Dose (08:00–09:00 AM with breakfast)—matches the body's natural circadian morning cortisol surge, thereby minimising hypothalamic-pituitary-adrenal (HPA) axis suppression and preventing night-time steroid insomnia!
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: No dose adjustment needed, but sodium/water retention can worsen oedema and hypertension in CKD. Hepatic: Prednisolone is already the biologically active form (unlike prednisone, which requires hepatic 11-beta-HSD1 activation), making prednisolone preferred in liver disease, though unbound fraction increases in hypoalbuminaemia.
Renal: No dose adjustment needed, but sodium/water retention can worsen oedema and hypertension in CKD. Hepatic: Prednisolone is already the biologically active form (unlike prednisone, which requires hepatic 11-beta-HSD1 activation), making prednisolone preferred in liver disease, though unbound fraction increases in hypoalbuminaemia.
Renal: No dose adjustment needed, but sodium/water retention can worsen oedema and hypertension in CKD. Hepatic: Prednisolone is already the biologically active form (unlike prednisone, which requires hepatic 11-beta-HSD1 activation), making prednisolone preferred in liver disease, though unbound fraction increases in hypoalbuminaemia.
7. Contraindications, Precautions & High-Risk Warnings
- DISTINGUISH REPLACEMENT vs ANTI-INFLAMMATORY THERAPY: Physiological adrenal replacement (e.g., Prednisolone 3–5 mg/day or Hydrocortisone 15–25 mg/day in divided doses) MUST NEVER BE STOPPED and requires DOUBLING ('Stress Dosing') during acute febrile illness, trauma, or surgery. Systemic anti-inflammatory courses >2–3 weeks (or >20 mg/day for >1 week) cause HPA axis suppression — NEVER stop abruptly (risk of fatal Addisonian adrenal crisis); taper gradually under medical supervision.
Key Clinical Precautions: Renal: No dose adjustment needed, but sodium/water retention can worsen oedema and hypertension in CKD. Hepatic: Prednisolone is already the biologically active form (unlike prednisone, which requires hepatic 11-beta-HSD1 activation), making prednisolone preferred in liver disease, though unbound fraction increases in hypoalbuminaemia.
8. Adverse Effects Profile
- Short-term: Marked postprandial and afternoon/evening hyperglycaemia, insomnia, increased appetite, fluid retention/sodium retention, blood pressure elevation, mood changes/irritability, dyspepsia. Long-term (>3 months): Cushingoid features (moon face, buffalo hump, central obesity), glucocorticoid-induced osteoporosis (vertebral/hip fractures), proximal myopathy, posterior subcapsular cataracts, glaucoma, skin thinning/easy bruising, reactivation of latent tuberculosis or fungal infections.
- Acute Adrenal Crisis upon abrupt withdrawal, peptic ulcer haemorrhage/perforation (especially if combined with NSAIDs or aspirin!), steroid psychosis/delirium, avascular necrosis of the femoral head (hip pain), severe opportunistic infections.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- NSAIDs (diclofenac, ibuprofen, aceclofenac) and Aspirin increase peptic ulcer and GI bleeding risk 4- to 10-fold (mandatory PPI gastroprotection needed!)
- Loop and thiazide diuretics cause severe additive hypokalaemia
- Antagonises oral antidiabetics and insulin (blood glucose rises sharply from noon to bedtime)
- CYP3A4 inducers (rifampicin, phenytoin, carbamazepine) double prednisolone clearance, reducing efficacy by ~50%
- Enhances fluoroquinolone-induced tendon rupture risk in the elderly!
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Write out the physician's step-down tapering calendar clearly by dates on the strip or patient card. Advise taking all tablets together with breakfast at 8:00 AM so sleep is not disturbed at night. Warn diabetics that blood sugars will climb during steroid courses and may require temporary insulin/OHA adjustment. Never take OTC painkillers (NSAIDs) while on Wysolone/Omnacortil.
- Meal & Clock Timing Instruction: Take WITH FOOD or MILK as a single morning dose between 07:00 and 08:00 AM (mimics physiological endogenous cortisol peak and minimises hypothalamic-pituitary-adrenal [HPA] axis suppression and nocturnal insomnia). (Single Morning Dose (08:00–09:00 AM with breakfast)—matches the body's natural circadian morning cortisol surge, thereby minimising hypothalamic-pituitary-adrenal (HPA) axis suppression and preventing night-time steroid insomnia!)
- Missed Dose Protocol: If on once-daily morning dosing, take with food as soon as remembered on the same day; if remembered the next morning, take only that day's scheduled dose. Never double.
- Geriatric Dispensing Pearl: In elderly CGHS patients taking Prednisolone ≥5–7.5 mg/day for ≥3 months, always verify co-prescription of Calcium + Vitamin D3 (and a bisphosphonate for glucocorticoid-induced osteoporosis prophylaxis) plus a PPI if also taking low-dose aspirin. Avoid combining with ciprofloxacin/levofloxacin due to Achilles tendon rupture risk.
Storage, Stability & Dispensing Safeguards: COLD CHAIN MANDATORY (2°C–8°C): Store in a pharmaceutical refrigerator between 2°C and 8°C; DO NOT FREEZE. Protect from light and heat during dispensing.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 06 [6.4] (p. 73)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.